Dicerna Pharmaceuticals, Inc.
Welcome to Novo Nordisk in the U.S. | Novo Nordisk U.S. Website
Watertown, United States · Founded 2015 · $172.0M raised
- Headquarters
- Watertown, Massachusetts
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- dicerna.com
- Total Funding
- $172.0M
- Last Round
- $70.0M Convertible NoteMar 2017
- Rounds
- 5
About
Dicerna Pharmaceuticals is a biopharmaceutical company and wholly owned subsidiary of Novo Nordisk, acquired in December 2021 for approximately $3.3 billion. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna develops RNAi-based therapies using its proprietary GalXC platform. Pipeline spans rare diseases, cardiometabolic conditions, and neurodegenerative diseases.
Summary
Dicerna Pharmaceuticals, Inc. is a Biotech company based in Watertown, United States, founded in 2015. It has raised $172.0M in total across 5 rounds, most recently a $70.0M Convertible Note round in Mar 2017. Investors include Domain Associates, SR One and Bain Capital.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2017
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...